No Data
Cardiff Oncology to Present at the Jefferies Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of canc
Cardiff Oncology to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society...
HC Wainwright & Co. : The Cardiff Oncology (CRDF.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.
HC Wainwright & Co. : The Cardiff Oncology (CRDF.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.
HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $14 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy and maintains $14 price target.
Cardiff Oncology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 300% HC Wainwright & Co. → $14 Reiterates Buy → Buy 03/06/2024 300% HC Wainwright & Co. $12 → $